Wall Street Journal - "Fighting Parkinson's Drug Side Effects"
Inhibiting A2a receptors could counteract some of the side effects of levodopa, according to Dr. C. Warren Olanow, a neurology professor at the Icahn School of Medicine at Mount Sinai. In a mid-stage clinical trial, tozadenant, being developed by Biotie and UCB, Inc., demonstrated a one-hour reduction in off-time for patients who received the optimal dose compared with placebo. Dr. Olanow, an investigator on a trial, presented findings last week at the annual meeting of the American Academy of Neurology in San Diego. Learn more